[go: up one dir, main page]

AR087392A1 - Combinacion antitumoral que comprende ombrabulina y cisplatino, asociada a radioterapia - Google Patents

Combinacion antitumoral que comprende ombrabulina y cisplatino, asociada a radioterapia

Info

Publication number
AR087392A1
AR087392A1 ARP120102781A ARP120102781A AR087392A1 AR 087392 A1 AR087392 A1 AR 087392A1 AR P120102781 A ARP120102781 A AR P120102781A AR P120102781 A ARP120102781 A AR P120102781A AR 087392 A1 AR087392 A1 AR 087392A1
Authority
AR
Argentina
Prior art keywords
ombrabulin
radiotherapy
cisplatin
antitumoral combination
antitumoral
Prior art date
Application number
ARP120102781A
Other languages
English (en)
Inventor
Celine Clemenson
Chantal Carrez
Eric Deutsch
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR087392A1 publication Critical patent/AR087392A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una combinación farmacéutica que comprende ombrabulina o AVE8062, que puede estar en forma de base o en forma de una sal farmacéuticamente aceptable y cisplatino, para su utilización como agente antitumoral destinado a pacientes tratados asimismo por radioterapia, que sufren especialmente cánceres y aún más particularmente tumores sólidos.
ARP120102781A 2011-08-01 2012-07-31 Combinacion antitumoral que comprende ombrabulina y cisplatino, asociada a radioterapia AR087392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1157040A FR2978662A1 (fr) 2011-08-01 2011-08-01 Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie

Publications (1)

Publication Number Publication Date
AR087392A1 true AR087392A1 (es) 2014-03-19

Family

ID=46832546

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102781A AR087392A1 (es) 2011-08-01 2012-07-31 Combinacion antitumoral que comprende ombrabulina y cisplatino, asociada a radioterapia

Country Status (5)

Country Link
AR (1) AR087392A1 (es)
FR (1) FR2978662A1 (es)
TW (1) TW201313225A (es)
UY (1) UY34232A (es)
WO (1) WO2013018017A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259598A (en) 1979-12-20 1981-03-31 General Electric Company Charge transfer signal processing apparatus transversal filter
ES2267255T3 (es) * 1998-04-03 2007-03-01 Ajinomoto Co., Inc. Agentes antitumorales.
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
DK1407784T3 (da) 2001-06-25 2011-02-28 Ajinomoto Kk Antitumormidler
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2009103076A1 (en) 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2945210B1 (fr) 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Also Published As

Publication number Publication date
WO2013018017A1 (en) 2013-02-07
UY34232A (es) 2013-02-28
FR2978662A1 (fr) 2013-02-08
TW201313225A (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
PH12017550063A1 (en) Combination therapies for treating cancers
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
CO6620019A2 (es) Métodos de tratamiento de cander de vejiga
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2015011753A (es) Metodos para tratar cancer de vegija.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
CR20120202A (es) Métodos y composiciones para tratar cáncer
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
EA201400178A1 (ru) Лечение рака молочной железы
WO2015009726A3 (en) Medical uses of cd38 agonists
UY36075A (es) Derivados de tubulisina
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
ECSP14013195A (es) Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata.
IN2014MN01944A (es)
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора
IL246065A0 (en) Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
AR087392A1 (es) Combinacion antitumoral que comprende ombrabulina y cisplatino, asociada a radioterapia

Legal Events

Date Code Title Description
FA Abandonment or withdrawal